AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 36356989
Drug: Bictegravir (BIC)
DrugBank: Bictegravir (DB11799)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bictegravir (BIC) 50 mg/emtricitabine (FTC) 200 mg/tenofovir alafenamide (TAF) 25 mg (Biktarvy) taken two times per day
Trial: 33345866
Drug: 20-mL liposomal
RxNorm normalized name: bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20-mL liposomal bupivacaine
Trial: 33345866
Drug: 20-mL 0.25%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20-mL 0.25% plain bupivacaine
Trial: 35798016
Drug: Cabozantinib 40
RxNorm normalized name: cabozantinib 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib 40 mg orally once daily plus atezolizumab 1200 mg intravenously every 3 weeks
Trial: 37499670
Drug: Sorafenib 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib 400 mg orally twice daily
Trial: 35798016
Drug: Single-agent cabozantinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-agent cabozantinib 60 mg orally once daily
Trial: 34598050
Drug: Parent-only social
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent-only social learning Cognitive Behavioral Therapy (SLCBT)
Trial: 34002707
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg mefenamic acid
Trial: 32842971
Drug: TAU +
RxNorm normalized name: Interferon tau
DrugBank: Interferon tau (DB16972)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAU + FNC (Treatment as Usual + Informal Social Network Intervention)
Trial: 32388522
Drug: Laser therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser therapy (diode laser, λ: 645 nm) administered for three consecutive days starting on day 1 (T0)
Trial: 35512252
Drug: Rosuvastatin, 10
RxNorm normalized name: Ezetimibe-Rosuvastatin, 10 mg-5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin, 10 mg daily
Trial: 35012310
Drug: PS-GOS-enriched beverage
RxNorm normalized name: Go-dry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PS-GOS-enriched beverage (2 g PS/day and 4.3 g GOS/day)
Trial: 34918714
Drug: Aloe ferox
RxNorm normalized name: Aloe ferox leaf
DrugBank: Aloe ferox leaf (DB14257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aloe ferox (460 mg, 2 capsules/day for 2 weeks, followed by a 2-week break, repeated 3 times)
Trial: 32894102
Drug: HIV-1-positive women,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV-1-positive women, treatment-naive, tested for transmitted drug resistance mutations (TDRM)
Trial: 34523108
Drug: Prothrombin complex
RxNorm normalized name: prothrombin complex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prothrombin complex concentrates (PCC); median dose 1,000 units
Trial: 34523108
Drug: Frozen plasma
RxNorm normalized name: Fresh frozen plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frozen plasma (FP); median dose 4 units
Trial: 33303389
Drug: Nightly sildenafil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nightly sildenafil 50 mg and sildenafil 100 mg on demand for sexual relations (up to 6 pills/month)
Trial: 33303389
Drug: Nightly sildenafil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nightly sildenafil 50 mg (5 nights/week) plus intracavernosal injections twice/week
Trial: 33303389
Drug: Nightly placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nightly placebo with sildenafil 100 mg on demand for sexual relations (up to 6 pills/month)
Trial: 38755585
Drug: Olaparib maintenance
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib maintenance therapy
Trial: 32591103
Drug: Active surveillance
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active surveillance (no maintenance therapy)
Trial: 32591103
Drug: Olaparib maintenance
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib maintenance therapy with 10% discount
Trial: 32591103
Drug: Olaparib maintenance
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib maintenance therapy with 20% discount
Trial: 32717350
Drug: Adaptive preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adaptive preventive intervention (API) designed to educate and motivate heavy-drinking college students; specific details on dosage and duration not available.
Trial: 32717350
Drug: Adaptive preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adaptive preventive intervention (API); specific details on dosage and duration not available.
Trial: 32792107
Drug: Cognitive-behavioural therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioural therapy plus small changes lifestyle intervention
Trial: 32107930
Drug: Insulin Degludec/Liraglutide
RxNorm normalized name: INSULIN DEGLUDEC/LIRAGLUTIDE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin Degludec/Liraglutide (IDegLira)
Trial: 32107930
Drug: Basal-Bolus (BB)
RxNorm normalized name: Dream Pure BB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal-Bolus (BB) therapy (once-daily insulin glargine 100 U/mL and insulin aspart ≤4 times/day)
Trial: 32623059
Drug: Immersive tutorial
RxNorm normalized name: OCTOCRYLENE 10 g in 100 g / HOMOSALATE 10 g in 100 g / AVOBENZONE 3 g in 100 g / OCTISALATE 4.5 g in 100 g TOPICAL LOTION [Eucerin Face immersive Hydration]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immersive tutorial in virtual reality (VR) as a teaching supplement
Trial: 33217593
Drug: Tamoxifen combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen combined with toremifene treatment
Trial: 33272311
Drug: Standard physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard physical therapy plus battlefield acupuncture
Trial: 34942595
Drug: High calcium
RxNorm normalized name: Nutritional Supplement Oral Liquid [ENSURE HIGH CALCIUM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High calcium pre-exercise meals (1,000 mg)
Trial: 34942595
Drug: Low calcium
RxNorm normalized name: Dianeal Low Calcium 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low calcium pre-exercise meals (<50 mg)
Trial: 34706268
Drug: Standard oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oral hygiene advice (control)
Trial: 34534233
Drug: Xanthine oxidase
RxNorm normalized name: Xanthine oxidase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xanthine oxidase inhibitors
Trial: 33065552
Drug: ticagrelor/aspirin (carriers)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ticagrelor/aspirin (carriers)
Trial: 33065552
Drug: clopidogrel/aspirin (carriers)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: clopidogrel/aspirin (carriers)
Trial: 33065552
Drug: ticagrelor/aspirin (non-carriers)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ticagrelor/aspirin (non-carriers)
Trial: 33065552
Drug: clopidogrel/aspirin (non-carriers)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: clopidogrel/aspirin (non-carriers)
Trial: 32022618
Drug: Terbinafine hydrochloride
RxNorm normalized name: Terbinafine Hydrochloride
DrugBank: Terbinafine (DB00857)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Terbinafine hydrochloride spray (THS) in combination with 3% boric acid alcohol (3% BAA) ear drops
Trial: 616826658
Drug: Daily diary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily diary control group
Trial: 33709238
Drug: Chinese medicine
RxNorm normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese medicine (CM) involving triple rehabilitation therapy (electro‐acupuncture, Chinese medicinal herb fumigating‐washing, and traditional exercises)
Trial: 33709238
Drug: Conventional rehabilitation
RxNorm normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional rehabilitation therapy (physical factor therapy, joint movement training, and muscle strength training)
Trial: 36187365
Drug: 12-week online
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-week online multicomponent stress reduction intervention including yoga, breathwork, meditation videos, cognitive behavioral therapy activities, and check-ins.
Trial: 36187365
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received weekly motivational messages by email.
Trial: 33278859
Drug: Fibrin glue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrin glue injection with combination therapy
Trial: 33278859
Drug: Fibrin glue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrin glue injection without combination therapy
Trial: 33278859
Drug: Fibrin glue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrin glue injection (overall population)
Trial: 34323681
Drug: lenabasum 5
RxNorm normalized name: Lenabasum
DrugBank: Lenabasum (DB12193)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lenabasum 5 mg twice daily
Trial: 34323681
Drug: lenabasum 20
RxNorm normalized name: Lenabasum
DrugBank: Lenabasum (DB12193)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lenabasum 20 mg twice daily
Trial: 35416465
Drug: 1000mg metamizole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000mg metamizole + 400mg ibuprofen
Trial: 33609324
Drug: Assessment of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assessment of drug treatment quality by three specialist physicians and two resident physicians
Trial: 33609324
Drug: Assessment of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assessment of the association between drug treatment and hospital admission
Trial: 32842975
Drug: Oral and
RxNorm normalized name: Tridate, oral and rectal kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral and written information about a home-based exercise programme (Control)
Trial: 34264860
Drug: Acupuncture plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture plus normal dose of Chinese herbal fumigation steam therapy (CHFST)
Trial: 34264860
Drug: Acupuncture plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture plus one-sixteenth of a normal dose of CHFST
Trial: 35125265
Drug: Group-based therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group-based therapy (GT)
Trial: 35125265
Drug: Email-delivered self-help
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Email-delivered self-help cognitive behavioral therapy (ESH)
Trial: 34128526
Drug: Vehicle (normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle (normal saline) injections
Trial: 34756640
Drug: High‐Intensity Laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High‐Intensity Laser Therapy (HILT)
Trial: 35404684
Drug: Fuzuloparib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fuzuloparib (150 mg, twice daily)
Trial: 38140184
Drug: 23-valent pneumococcal
RxNorm normalized name: Streptococcus pneumoniae type 1 capsular polysaccharide antigen
DrugBank: Streptococcus pneumoniae type 1 capsular polysaccharide antigen (DB10319)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 23-valent pneumococcal polysaccharide vaccine (PPSV23)
Trial: 33142249
Drug: Dexmedetomidine 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.4 μg/ml
Trial: 33142249
Drug: Dexmedetomidine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.5 μg/ml
Trial: 33142249
Drug: Dexmedetomidine 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.6 μg/ml
Trial: 33142249
Drug: Dexmedetomidine 0
RxNorm normalized name: dexmedetomidine 0.12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0 μg/ml
Trial: 33142249
Drug: Dexmedetomidine 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.3 μg/ml
Trial: 39251616
Drug: Norepinephrine administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine administration
Trial: 33031148
Drug: Clinically important
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinically important treatment benefit or harm
Trial: 35907504
Drug: Low-dose Prasugrel
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose Prasugrel or Clopidogrel
Trial: 34668436
Drug: 75 g
RxNorm normalized name: Zosyn 3.375 GM Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 g of ketone ester (KE)
Trial: 34668436
Drug: 300 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg/kg body mass bicarbonate (BIC)
Trial: 34668436
Drug: Control drink
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control drink with 60 g of carbohydrates/h
Trial: 36102630
Drug: 2-week postoperative
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2-week postoperative oral antibiotics
Trial: 36102630
Drug: 12-week postoperative
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-week postoperative oral antibiotics
Trial: 33714226
Drug: Intensive glycemic
RxNorm normalized name: Glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive glycemic control (exenatide and pioglitazone or basal-bolus insulin)
Trial: 35538000
Drug: Standard oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oral and written information
Trial: 35538000
Drug: Standard oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oral and written information plus additional educational video
Trial: 32976051
Drug: Olive pâté
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive pâté (4 tablets/day corresponding to 30 mg/day of hydroxytyrosol)
Trial: 32232698
Drug: Tailored dose-dense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored dose-dense chemotherapy (four cycles of epirubicin and cyclophosphamide every 2 weeks followed by four cycles of docetaxel every 2 weeks)
Trial: 32232698
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy (three cycles of fluorouracil and epirubicin-cyclophosphamide every 3 weeks followed by three cycles of docetaxel every 3 weeks)
Trial: 33428901
Drug: Extracorporeal life
RxNorm normalized name: Life-O-Gen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extracorporeal life support (ECLS) in addition to early revascularization with percutaneous coronary intervention or coronary artery bypass grafting and optimal medical treatment
Trial: 36173031
Drug: Synbiotics capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synbiotics capsule plus anti-inflammatory-antioxidant rich diet
Trial: 36173031
Drug: Placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule plus dietary recommendations
Trial: 34184929
Drug: Testosterone levels
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone levels during androgen deprivation therapy (ADT)
Trial: 35373693
Drug: NB‐UVB monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NB‐UVB monotherapy
Trial: 32216909
Drug: Alteplase 20
RxNorm normalized name: alteplase 20 mg INTRAVEN VIAL (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alteplase 20 mg
Trial: 32216909
Drug: Alteplase 10
RxNorm normalized name: alteplase 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alteplase 10 mg
Trial: 33334450
Drug: High-dose Dobutamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose Dobutamine (DBT) (40 to 50 μg/kg/min for 10 min)
Trial: 33334450
Drug: High-dose Isoproterenol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose Isoproterenol (IPN) (20 to 30 μg/min for 10 min)
Trial: 33592825
Drug: Modified selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified selective spinal massage method combined with basic rehabilitation treatment
Trial: 33592825
Drug: Basic rehabilitation
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic rehabilitation treatment
Trial: 35689890
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C supplementation (2000 mg/d)
Trial: 35689890
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C supplementation (2000 mg/d) in male participants
Trial: 35689890
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C supplementation (2000 mg/d) in female participants
Trial: 33075197
Drug: 10% sinecatechins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% sinecatechins ointment applied three times daily for 16 weeks
Trial: 33075197
Drug: Placebo ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ointment applied three times daily for 16 weeks
Trial: 32899037
Drug: Mirogabalin 10
RxNorm normalized name: mirogabalin
DrugBank: Mirogabalin (DB11825)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Mirogabalin 10 or 15 mg twice daily (BID)
Trial: 32052264
Drug: Mirogabalin 15
RxNorm normalized name: mirogabalin
DrugBank: Mirogabalin (DB11825)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Mirogabalin 15 mg BID
Trial: 32899037
Drug: Mirogabalin (flexible
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirogabalin (flexible dosing)
Trial: 36472718
Drug: Square-wave insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Square-wave insulin bolus (SQ)
Trial: 32007123
Drug: Negative pressure
RxNorm normalized name: DRESSING,NEGATIVE PRESSURE WOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative pressure wound therapy (NPWT) applied post-surgery, maintaining negative pressure at -125 mmHg for five days.
Trial: 32200266
Drug: Immediate oral
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate oral intake of low-fat solid food (15 g/d)
Trial: 35026964
Drug: Sham ultrasound
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham ultrasound treatment (Control)
Trial: 33338325
Drug: Multimodal occupational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal occupational therapy (including patient education, hand exercises, orthoses, and assistive devices)
Trial: 33338325
Drug: Usual treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual treatment (OA information)
Trial: 35045228
Drug: SER-109 (four
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SER-109 (four capsules daily for 3 days)
Trial: 35045228
Drug: Placebo (four
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (four capsules daily for 3 days)
Trial: 33051650
Drug: Amphotericin monotherapy
RxNorm normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin monotherapy
Trial: 32206786
Drug: 6-month regimen
RxNorm normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-month regimen alternating intravenous and oral glucocorticoids with an alkylating agent every other month
Trial: 32206786
Drug: Cyclical therapy
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclical therapy (glucocorticoids and alkylating agent)
Trial: 32206786
Drug: Mycophenolate salts
RxNorm normalized name: mycophenolate
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mycophenolate salts and adrenocorticotropic hormone
Trial: 34499904
Drug: Antibiotic group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic group (3 g of ampicillin-sulbactam administered just before, 8 hours after, and the morning after ESD)
Trial: 34499904
Drug: Nonantibiotic group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonantibiotic group (conventional treatment)
Trial: 33180897
Drug: Alternative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative treatment options for hypertension (HTN)
Trial: 33180897
Drug: Alternative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative treatment options for type II diabetes mellitus (T2DM)
Trial: 33180897
Drug: Alternative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative treatment options for hyperlipidemia (HL)
Trial: 32376724
Drug: Apatinib (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib (500 mg orally once daily) plus Camrelizumab (200 mg intravenously every 2 weeks)
Trial: 34878650
Drug: IL-1 receptor
RxNorm normalized name: IL-1 TRAP
DrugBank: Rilonacept (DB06372)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IL-1 receptor antagonist (Anakinra)
Trial: 33185373
Drug: Paravertebral block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paravertebral block using 25 mg bupivacaine plus 8 mg dexamethasone in a total volume of 10 mL twice one week apart (Group I)
Trial: 33185373
Drug: Paravertebral block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paravertebral block using 25 mg bupivacaine plus 8 mg dexamethasone in a total volume of 10 mL 3 times one week apart (Group II)